https://www.selleckchem.com/pr....oducts/etomoxir-na-s
To address these gaps, we propose a precision medicine approach in which clinical trialsselectively enroll patients based upon their physiological receptivity to targeted therapies, and therapeutic effects are measured by complementary behavioral, neuroimaging, and electrophysiologic endpoints. This personalized approach can be realized through rigorous clinical trial design and international collaboration, both of which will be essential for advancing the development of new therapies and ultimately improving the lives of patie